JMP Securities analyst Liisa Bayko noted that the FDA recently communicated to Sarepta Therapeutics (SRPT) that it would allow a statistically significant increase in de novo truncated dystrophin to serve as the basis for accelerated approval for golodirsen. She thinks this could also open the door for Summit Therapeutics (SMMT) to utilize utrophin as a potential biomarker for accelerated approval of ezutromid, its own Duchenne muscular dystrophy candidate, adding that she sees an accelerated path as upside to her valuation. Bayko keeps an Outperform rating and $42 price target on Summit shares.